Eyenovia Announces Closing of Public Offering
August 23, 2024 11:42 ET
|
Eyenovia, Inc.
NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today the closing of its public offering of...
Eyenovia Announces Pricing of $5.14 Million Public Offering
August 21, 2024 09:29 ET
|
Eyenovia, Inc.
NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it has agreed to sell 12,850,000...
Eyenovia, Inc. Announces Proposed Public Offering
August 20, 2024 17:09 ET
|
Eyenovia, Inc.
NEW YORK, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it intends to offer and sell...
Eyenovia to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
August 13, 2024 07:00 ET
|
Eyenovia, Inc.
NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide and phenylephrine hydrochloride ophthalmic spray)...
Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 12, 2024 16:05 ET
|
Eyenovia, Inc.
Following FDA consultation, announced plans for validation of the Gen-2 Optejet® device and 2025 regulatory submission with Mydcombi™ as lead product Advanced Phase 3 CHAPERONE study of MicroPine as...
Eyenovia to Report Second Quarter 2024 Results on Monday, August 12th
August 08, 2024 07:00 ET
|
Eyenovia, Inc.
NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, today...
Eyenovia and Formosa Pharmaceuticals Initiate Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S.
August 07, 2024 17:11 ET
|
Eyenovia, Inc.
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive...
Eyenovia & SGN Nanopharma Announce Collaboration Agreement to Develop Novel Treatment for Chronic Dry Eye Disease
July 30, 2024 08:00 ET
|
Eyenovia, Inc.
NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive...
Eyenovia and Senju Pharmaceutical Co., Ltd. Sign Collaboration Agreement for Potential New Treatment for Chronic Dry Eye Disease
July 23, 2024 07:00 ET
|
Eyenovia, Inc.
Collaboration to focus on the development of a formulation of Senju’s SJP-0035 for use with Eyenovia’s Optejet® dispensing technology, following consultation with FDA Chronic dry eye estimated to be...
Eyenovia Announces Pricing of $5M Registered Direct Offering
June 28, 2024 08:00 ET
|
Eyenovia, Inc.
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it has entered into a securities...